OncoMatch/Clinical Trials/NCT07071714
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Is NCT07071714 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including SHR-8068 and Adebrelimab for colorectal cancer.
Treatment: SHR-8068 · Adebrelimab · Bevacizumab — The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic antitumor therapy
Part B: Systemic antitumor therapy was received 4 weeks before the start of the study.
Cannot have received: palliative radiotherapy
Part B: Palliative radiotherapy was completed within 14 days before the first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07071714 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic antitumor therapy, palliative radiotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages